博雅生物(300294.SZ):廖昕晰方面減持期過半 未減持公司股份
格隆匯12月1日丨博雅生物(300294.SZ)公佈,截至2021年12月1日,股東廖昕晰、嘉頤投資、大正初元(簡稱“計劃減持主體”)披露的減持計劃實施時間過半,計劃減持主體尚未通過集中競價、大宗交易等合法合規的方式減持公司股份。
廖昕晰為公司董事長;嘉頤投資系廖昕晰及其配偶共同出資設立,廖昕晰持有其80%財產份額;廖昕晰持有大正初元60%股權,廖昕晰能夠實際控制大正初元。
截至目前,計劃減持主體合計持有公司股份1642.8778萬股,佔公司總股本的3.2581%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.